{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:34:23Z","timestamp":1787319263478,"version":"build-2736575974"},"reference-count":131,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 ligands are highly expressed in some CD30+ large cell lymphomas, including classic Hodgkin lymphoma (CHL), primary mediastinal large B-cell lymphoma (PMBL), Epstein\u2013Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL), and anaplastic large cell lymphoma (ALCL). The genetic alteration of the chromosome 9p24.1 locus, the location of PD-L1, PD-L2, and JAK2 are the main mechanisms leading to PD-L1 and PD-L2 overexpression and are frequently observed in these CD30+ large cell lymphomas. The JAK\/STAT pathway is also commonly constitutively activated in these lymphomas, further contributing to the upregulated expression of PD-L1 and PD-L2. Other mechanisms underlying the overexpression of PD-L1 and PD-L2 in some cases include EBV infection and the activation of the mitogen-activated protein kinase (MAPK) pathway. These cellular and molecular mechanisms provide a scientific rationale for PD-1\/PD-L1 blockade in treating patients with relapsed\/refractory (R\/R) disease and, possibly, in newly diagnosed patients. Given the high efficacy of PD-1 inhibitors in patients with R\/R CHL and PMBL, these agents have become a standard treatment in these patient subgroups. Preliminary studies of PD-1 inhibitors in patients with R\/R EBV+ DLBCL and R\/R ALCL have also shown promising results. Future directions for these patients will likely include PD-1\/PD-L1 blockade in combination with other therapeutic agents, such as brentuximab or traditional chemotherapy regimens.<\/jats:p>","DOI":"10.3390\/biomedicines10071587","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T11:15:05Z","timestamp":1656933305000},"page":"1587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["PD-1\/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-7666","authenticated-orcid":false,"given":"Wei","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ishida, Y. (2020). PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells, 9.","DOI":"10.3390\/cells9061376"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Garcia-Lacarte, M., Grijalba, S.C., Melchor, J., Arnaiz-Leche, A., and Roa, S. (2021). The PD-1\/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers, 13.","DOI":"10.3390\/cancers13184683"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","article-title":"Immune checkpoint blockade: Releasing the brake towards hematological malignancies","volume":"30","author":"Xia","year":"2016","journal-title":"Blood Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 Pathway from Discovery to Clinical Implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019001043","article-title":"A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/OP.20.01020","article-title":"PD-1 Blockade in Classic Hodgkin Lymphoma","volume":"17","author":"Ansell","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"59976","DOI":"10.18632\/oncotarget.11045","article-title":"PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: Clinicopathologic features and prognostic implications","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/OP.20.00771","article-title":"Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma","volume":"17","author":"Lee","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: Update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: Implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Diaz, T., Navarro, A., Ferrer, G., Gel, B., Gaya, A., Artells, R., Bellosillo, B., Garcia-Garcia, M., Serrano, S., and Martinez, A. (2011). Lestaurtinib inhibition of the Jak\/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018856"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.leu.2403750","article-title":"STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis","volume":"19","author":"Holtick","year":"2005","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: A review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group","volume":"29","author":"Borchmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Gerrie","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): A multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: Results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: Phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12967-018-1689-y","article-title":"Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma","volume":"16","author":"Kwon","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tranon.2018.12.008","article-title":"STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma","volume":"12","author":"Tamma","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-14-0683","article-title":"Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: Refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: A LYSA Study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Savage, K.J. (2021). Primary mediastinal Large B-cell Lymphoma. Blood.","DOI":"10.1182\/blood.2020008376"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20406207211048959","DOI":"10.1177\/20406207211048959","article-title":"Current and emerging treatment options in primary mediastinal B-cell lymphoma","volume":"12","author":"Fakhri","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1002\/cam4.4198","article-title":"EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency","volume":"10","author":"Satou","year":"2021","journal-title":"Cancer Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: A nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/gcc.22249","article-title":"Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"54","author":"Yoon","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"key":"ref_88","first-page":"40","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review","volume":"52","author":"Salas","year":"2020","journal-title":"Pathology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","article-title":"Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified","volume":"5","author":"Bourbon","year":"2021","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.25112","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Castillo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Odqvist","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cas.12389","article-title":"Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways","volume":"105","author":"Kato","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.17708","article-title":"EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK\/STAT (STAT3) pathway mutations and unique clinicopathologic features","volume":"194","author":"Chapman","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1683346","DOI":"10.1080\/2162402X.2019.1683346","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture\/presentation and hijacked T-cell suppression","volume":"9","author":"Jiang","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Quan, L., Chen, X., Liu, A., Zhang, Y., Guo, X., Yan, S., and Liu, Y. (2015). PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136476"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1097\/CAD.0000000000001187","article-title":"Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: A case report","volume":"33","author":"Yu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2021-151824","article-title":"Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas","volume":"138","author":"Yilmaz","year":"2021","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V73.3.806.806","article-title":"A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis","volume":"73","author":"Kaneko","year":"1989","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","article-title":"CD30-positive large cell lymphomas (\u2018Ki-1 lymphoma\u2019) are associated with a chromosomal translocation involving 5q35","volume":"74","author":"Mason","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Jaffe","year":"2014","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41379-019-0336-3","article-title":"PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma","volume":"33","author":"Shen","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2021.1881511","article-title":"PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements","volume":"62","author":"Manso","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.3324\/haematol.2018.205880","article-title":"DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK\/STAT surrogate markers","volume":"104","author":"Onaindia","year":"2019","journal-title":"Haematologica"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2017.103","article-title":"PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma","volume":"31","author":"Atsaves","year":"2017","journal-title":"Leukemia"},{"key":"ref_115","first-page":"3692","article-title":"Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma","volume":"9","author":"Khoury","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Andersson, E.I., Bruck, O., Braun, T., Mannisto, S., Saikko, L., Lagstrom, S., Ellonen, P., Leppa, S., Herling, M., and Kovanen, P.E. (2020). STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(-) ALCL. Cancers, 12.","DOI":"10.3390\/cancers12030702"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","article-title":"B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"123253","DOI":"10.1155\/2012\/123253","article-title":"NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases","volume":"2012","author":"Pearson","year":"2012","journal-title":"J. Signal Transduct."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: Efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e26902","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann. Intern Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100832","DOI":"10.1016\/j.blre.2021.100832","article-title":"Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas","volume":"50","author":"Bednarska","year":"2021","journal-title":"Blood Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant-associated anaplastic large cell lymphoma","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","article-title":"Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma","volume":"34","author":"Clemens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/s41379-021-00842-6","article-title":"Breast implant-associated anaplastic large cell lymphoma: Clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease","volume":"34","author":"Evans","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_128","first-page":"360","article-title":"Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL","volume":"135","author":"Laurent","year":"2020","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"36126","DOI":"10.18632\/oncotarget.26308","article-title":"Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma","volume":"9","author":"Blombery","year":"2018","journal-title":"Oncotarget"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/tbj.14205","article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway","volume":"27","author":"Quesada","year":"2021","journal-title":"Breast J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2019.05.007","article-title":"Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas","volume":"90","author":"Tabanelli","year":"2019","journal-title":"Hum. Pathol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:42:23Z","timestamp":1760139743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":131,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071587"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071587","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]}}}